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12p70 secretion, naive CD4 T cell expansion, Th1 and Tc1 cells
differentiation) in the context of RIC allo-SCT. The ﬁne functions
of immune effectors would tend to be more evident in such less
toxic regimens, offering new opportunities for a better understand-
ing of aGVHD pathophysiology and therapy.
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RAPAMYCIN ADDED TO HUMAN CD25 CELL CULTURES ACTIVATED
THROUGH CD3/CD28 ENRICHES FOR CD4CD25CD27Foxp3
REGULATORY T CELLS
Keever-Taylor, C.A., Browning, M.B., Johnson, B.D., Truitt, R.L.,
Behn, B.A. Medical College of Wisconsin, Milwaukee, WI.
CD4 T cells that constitutively express high levels of CD25
inhibit T-cell responses in a dose-dependent manner. Methods to
isolate and expand CD4CD25 regulatory T-cells (Tregs) have
been developed to allow for potential clinical use in regulating
undesired T cell-mediated responses such as autoimmune disease
or GVHD. We have enriched for Tregs by CD25 positive selec-
tion followed by culture in ex vivo 15-5% HS and autologous
feeder cells. Activation is through a single addition of CD3/CD28
Ab-linked beads (4:1 bead:cell) and IL-2 (100 U/mL added d 3).
Cultures with potent suppressor activity expanded on average 450
fold in 14 d when maintained at 5  105/mL in medium  IL-2.
However, by 21 d suppressor activity greatly diminished and the %
of CD25-bright cells decreased, indicating activated non-Treg
cells were dominating the cultures. To increase the purity of Tregs
we explored the use of rapamycin, a T cell immunosuppressive
agent recently shown to selectively spare murine Tregs. Rapamy-
cin (20-0.01 ng/mL) added to CD25-enriched cells signiﬁcantly
inhibited cell expansion at doses 1 ng/mL that was inversely
correlated with enhanced suppressor activity at days 10 and 21.
Cultures without rapamycin expanded on average 17,000 fold by
day 21 vs 350 fold with 1 ng/mL rapamycin. By 21 d cells from
untreated cultures suppressed allo-proliferation by only 28% at a
1:1 suppressor:responder ratio compared to 63  20% by cells
grown in 1 ng/mL rapamycin (P  .007). The %
CD4CD25bright cells at 10 d and 21 d was higher in rapamycin-
containing cultures than untreated cultures, P  .003. Intracellular
FACS staining for the transcription factor Foxp3, a marker for
Tregs, showed signiﬁcantly higher expression on CD4 cells from
10 d rapamycin containing cultures with 23  6% Foxp3CD4
cells vs 5  3% in cultures without rapamycin (P  .03, n  4).
Foxp3 was predominately expressed on CD4CD25-bright cells
that also co-expressed CD27-bright. By day 21 cultures grown in
rapamycin contained 1000 to 5000 fold more CD4Foxp3 cells
than 10 d cultures without rapamycin. Only 0.7% of CD4 cells
from CD4CD25-neg cells cultured with rapamycin expressed
Foxp3. Optimal Foxp3 expression required continued presence of
rapamycin in culture and addition at culture initiation was superior
to addition at day 3. In summary, addition of rapamycin at doses
from 1-20 ng/mL to CD25-enriched cell cultures increased the
purity of cells with the phenotype and function of Tregs.
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PROSPECTIVE EVALUATION OF A GvHD-SPECIFIC PROTEOMICS PAT-
TERN AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
Weissinger, E.M.1, Hillmann, M.2, Dammann, E.1, Kolb, H.-J.3,
Holler, E.4, Mischak, H.2, Ganser, A.1, Hertenstein, B.5 1Hannover
Medical School, Hannover, Germany; 2Mosaiques Diagnostics GmbH,
Hannover, Germany; 3Ludwig-Maximilians-University, Munich, Ger-
many; 4University of Regensburg, Regensburg, Germany; 5Klinikum
Bremen Mitte gGmbH, Bremen, Germany.
We have recently published a polypeptide pattern speciﬁc for the
early diagnosis of acute graft versus host disease (aGvHD), based
on the application of capillary electrophoresis (CE) and mass spec-
trometry (MS). Here we report the application of aGvHD-speciﬁc
patterns to prospectively collected samples from 86 patients (45
AML, 14 ALL, 8 MM, 5 CLL, 5 SAA, 3 MDS, 3CML, 3 NHL).
Fifty-three patients were transplanted from matched unrelated
donors (MUD), 29 received stem cells from matched related do-
nors (MRD), 3 from haplo-identical donors and 1 was transplanted
from a syngeneic sibling. In the majority of the patients the GvHD
prophylaxis was methotrexate or mycophenolate and cyclosporin
A. Urine samples were collected on ice prior to conditioning,
weekly until discharge from the ward and monthly thereafter.
Immediate freezing of the samples avoids degradation of the pro-
teins/peptides. After thawing and removal of confounding sub-
stances like salts and of all molecules larger than 30 kDa, the
samples were loaded onto the CE, separated according to their
charge and, after ionization, directly analyzed in an electrospray-
ionization time-of-ﬂight (ESI-TOF)-MS. Between 500 and 2500
peptides and proteins were detected in individual samples. All data
generated are stored in a Microsoft MS database. The polypeptide
patterns speciﬁc for the early detection of acute GvHD were
applied to the data from the prospectively and blinded collected
samples. The outcome of these analyses was compared to the
clinical diagnosis of aGvHD, sepsis and CMV-reactivation. In 362
samples screened, 112 scored positive with the GvHD pattern.
Twenty-eight of those were false positive, mainly at the time of
conditioning, but only 3 were scored false negative. Thus the
sensitivity of the aGvHD pattern is about 96% with a 75% positive
prediction value, the speciﬁcity is about 89% with a negative
prediction value of 98%. Thus the application of the aGvHD
pattern for early recognition of acute GvHD is very useful for
predicting the development of aGvHD. Seven patients in the
prospective cohort have developed cGvHD so far and samples
were also scored with the aGvHD pattern. First results show that
in the majority of the patients the polypeptides excreted do not
correspond to those forming the aGvHD pattern. Taken together
our results demonstrate that the proteome analysis of body ﬂuids
collected from patients after HSCT maybe extremely useful for
diagnosis of complications.
HISTOCOMPATIBILITY/ALTERNATIVE
STEM CELL SOURCES
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UMBILICAL CORD BLOOD TRANSPLANTATION IN PEDIATRIC PA-
TIENTS: RESULTS OF THE PROSPECTIVE, MULTI-INSTITUTIONAL CORD
BLOOD TRANSPLANTATION STUDY (COBLT)
Kernan, N.A.1, Carter, S.L.2, Wagner, J.E.3, Baxter-Lowe, L.4,
Wall, D.5, Kapoor, N.6, Guinan, E.7, Wagner, E.8, Geller, N.8,
Kurtzberg, J.9 1Memorial Sloan-Kettering Cancer Center, New York,
NY; 2The EMMES Corporation, Rockville, MD; 3University of Min-
nesota, Minneapolis, MN; 4University of California, San Francisco, CA;
5Texas Transplant Institute, San Antonio, TX; 6Children’s Hospital of
Los Angeles, Los Angeles, CA; 7Dana Farber Cancer Institute, Boston,
MA; 8The National Heart, Lung and Blood Institute, Bethesda, MD;
9Duke University Medical Center, Durham, NC.
In 1996, NHLBI sponsored COBLT, a prospective study that
established 3 cord blood banks that banked8000 CBUs, and funded
28 transplant centers to participate in a clinical trial with the primary
endpoint of 180-day post-transplant overall survival (OS). The trial
enrolled 316 pediatric pts with median age 4.6 years (range 0.1-17.9),
61% M, 37% minorities, 44% CMV and 71% with a malignant
(malign) disease, who received a single CBU. CBUs had to be at least
4 of 6 HLA match (intermediate resolution A and B and high reso-
lution [HR] DRB1) and provide a total nucleated cell dose (TNC)
1.0  107/kg. Approximately 50% of Caucasian and Hispanic pts
received a CBU matched at HLA 5-6/6, but only 15% of African-
Americans and 36% of Asians were matched at HLA 5-6/6. HRHLA
types were retrospectively determined for HLA -A, -B, -DRB1 (292
pairs) and -C and -DQB1 (270 pairs). Only 30% of pairs were HR
HLA matched at 8-10 alleles. The median pre-cryopreservation
TNC and CD34 cell dose were 6.8  107/kg (range 1.5-50.4) and
2.3 105/kg (range 0.1-20.1), respectively. The cumulative incidence
(CINC) of neutrophil recovery (	500, day 42) and of platelet engraft-
ment (	50000, day 180) was 81% and 54%, respectively. By day
100, the CINC of grades II-IV aGVHD was 40%. The CINC of
cGVHD was 21% at 2 yrs. The probability of OS at 180 days
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